NEUREN PHARMACEUTICALS
Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone. Neuren has three lead candidates; Motiva™ and NNZ-2566 presently in clinical de... velopment to treat three different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).
NEUREN PHARMACEUTICALS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2004-01-01
Address:
Camberwell South, Victoria, Australia
Country:
Australia
Website Url:
http://www.neurenpharma.com
Total Employee:
11+
Status:
Active
Contact:
+61390920480
Email Addresses:
[email protected]
Total Funding:
21.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Content Delivery Network Font Awesome Microsoft Exchange Online Amazon
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Stock Details
Official Site Inspections
http://www.neurenpharma.com Semrush global rank: 4.52 M Semrush visits lastest month: 2.36 K
- Host name: a290d26420470737c.awsglobalaccelerator.com
- IP address: 15.197.133.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neuren Pharmaceuticals"
Neuren Pharmaceuticals
Neuren (ASX: NEU) has two drugs in clinical development for multiple serious neurological disorders that emerge in early childhood, for which currently there are no approved drug …See details»
Company Overview - Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX: NEU) is developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by …See details»
Corporate Directory - Neuren Pharmaceuticals
Corporate Directory. Neuren (ASX: NEU) has two drugs in clinical development for multiple serious neurological disorders that emerge in early childhood, for which currently there are no …See details»
Neuren Pharmaceuticals - Craft
Oct 4, 2024 · Neuren Pharmaceuticals is a company that develops therapies for debilitating neurodevelopmental disorders that are characterised by impaired connections and signalling …See details»
Neuren Pharmaceuticals - Crunchbase Company Profile & Funding
Neuren Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of brain injuries and neurodegeneration. Neuren Pharmaceuticals has garnered significant …See details»
Neuren Pharmaceuticals Limited | LinkedIn
Neuren Pharmaceuticals (ASX: NEU) is developing new therapies for six debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by …See details»
Company Neuren Pharmaceuticals Limited - MarketScreener.com
Mar 4, 2002 · Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug …See details»
Neuren Pharmaceuticals Ltd, NEU:ASX profile - FT.com
6 days ago · Neuren Pharmaceuticals Ltd (NEU:ASX) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Executive Management - Neuren Pharmaceuticals
Chief Business Officer. Neuren (ASX: NEU) has two drugs in clinical development for multiple serious neurological disorders that emerge in early childhood, for which currently there are no …See details»
Neuren Pharmaceuticals - PitchBook
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms …See details»
Overview, News & Similar companies - ZoomInfo.com
View Neuren Pharmaceuticals (www.neurenpharma.com) location in Victoria, Australia , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Neuren Pharmaceuticals Limited - Company Profile Report
Dec 31, 2019 · Neuren Pharmaceuticals Limited is a biopharmaceutical company that develops drugs for neurological disorders such as Trofinetide (NNZ-2566) for Rett syndrome and Fragile …See details»
Neuren Phase 2 trial shows significant improvements in Phelan …
MELBOURNE, Australia, Dec. 18, 2023 /PRNewswire/ -- Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with …See details»
Neuren Pharmaceuticals Limited to Obtain Late Stage Compound …
Jul 31, 2007 · Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren …See details»
Neuren Pharmaceuticals Limited (NURPF) - Yahoo Finance
Find the latest Neuren Pharmaceuticals Limited (NURPF) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce …
Aug 6, 2018 · The mission of the organization is to accelerate the full spectrum research to cure Rett syndrome and empower families with information, knowledge and connectivity. Further …See details»
Neuren Pharmaceuticals Limited ANNUAL REPORT 2020
1. Realise Neuren’s share of trofinetide value in the US through ACADIA’s Phase 3 results and New Drug Application. Phase 3 results Q4 2021. Potential US approval 2022. 2. Implement …See details»
FDA drug approval lifts biotech Neuren to $1b valuation
Mar 13, 2023 · Biotech Neuren Pharmaceuticals surged to a $1 billion valuation on Monday after the US healthcare regulator, the Food & Drug Administration, approved its trofinetide drug for …See details»
Neuren Non-Confidential Presentation - Neuren Pharmaceuticals
NEUREN’S BUSINESS SUMMARY. Significant commercial opportunities with no approved drug therapies. Strong support from leading physicians and patient advocacy groups. Using …See details»
Corporate Directory | Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited Suite 201, 697 Burke Road Camberwell, VIC 3124 Australia Phone: +61 (3) 9092 0480 Email: [email protected]See details»